ClinicalTrials.Veeva

Menu

FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status and phase

Terminated
Phase 2

Conditions

Stroke, Acute

Treatments

Drug: DFIL
Drug: NINDS

Study type

Interventional

Funder types

Other

Identifiers

NCT00132509
2000.208

Details and patient eligibility

About

Data from the literature have suggested that a longer time of thrombolysis might be more effective in ischemic stroke. We, the investigators at Hospices Civils de Lyon, have designed a randomized protocol to test this hypothesis. Moreover, the therapeutic window is 7 hours.

Rt-PA (alteplase) is injected intravenously in the 2 arms of the study for a duration of 60 minutes in the arm with a "classical dose" and 90 minutes in the arm with a "low dose-longer infusion".

This is a study of the outcome at 90 days.

Enrollment

500 estimated patients

Sex

All

Ages

18 to 81 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Symptoms of ischemic stroke
  • Presence of a deficit measurable with National Institutes of Health Stroke Scale (NIHSS)
  • Lack of any hemorrhagic lesion on the computed tomography (CT) scan at entry
  • Time of therapy less than 7 hours after onset of stroke
  • Permanent or aggravating symptoms
  • Ages 18-81

Exclusion criteria

  • Lack of cerebral infarction or of cranial trauma within 3 weeks before therapy
  • No surgery within 14 days before therapy
  • History of cerebral bleeding
  • Blood pressure: systolic >185 mmHg and/or diastolic >110 mmHg
  • Minor symptoms or symptoms rapidly improving
  • Gastro-intestinal or urinary hemorrhage within 21 days
  • Arterial puncture within 7 days before therapy
  • Epileptic seizure at the beginning of stroke
  • Patients under oral anticoagulants or having received heparin within 48 hours, and with elevated activated partial thromboplastin time (aPTT)
  • Patients with elevated International Normalized Ratio (INR) or thrombocyte count < 100 x 10^9
  • Blood glucose value < 2.7 mmol/l or > 22.2 mmol/l
  • Cardiac, pulmonary, hepatic or renal failure, not allowing a study over 3 months
  • History of gastric ulcer within 15 days; gestation and menstruation

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

500 participants in 2 patient groups

DFIL
Experimental group
Treatment:
Drug: DFIL
NINDS
Active Comparator group
Treatment:
Drug: NINDS

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems